Insulet Q3 2025 Results Exceed Expectations, Omnipod Expansion, and Upgraded Guidance Drive Strong Valuation

Saturday, Nov 8, 2025 3:31 am ET1min read
PODD--

Insulet delivered Q3 2025 results surpassing analyst predictions due to strong Omnipod expansion. The company boosted full-year guidance, with shares rallying and guidance continually raised. The stock is now undervalued at $365.96, with room for upside based on updated growth and margin expectations. However, reliance on a single core product and global competition pose risks to Insulet's growth story.

Insulet Q3 2025 Results Exceed Expectations, Omnipod Expansion, and Upgraded Guidance Drive Strong Valuation

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet